Literature DB >> 17545839

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling.

Andrew Thorburn1.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo1L is a death ligand, a cytokine that activates apoptosis through cell surface death receptors. TRAIL is thought to be important in host tumor surveillance and metastasis suppression, and various therapeutic agonists that activate TRAIL receptors to induce tumor cell apoptosis are in clinical development. This review discusses recent findings about TRAIL pathway signaling and relates the signaling mechanisms to issues that need to be considered as we try to manipulate TRAIL signaling to treat cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545839     DOI: 10.1097/JTO.0b013e31805fea64

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  26 in total

1.  Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents.

Authors:  Christina Menke; Lianghua Bin; Jacqueline Thorburn; Kian Behbakht; Heide L Ford; Andrew Thorburn
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

2.  TNF related apoptosis-inducing ligand and its receptors in ocular tumors.

Authors:  Qian Ning; Lei Hou; Min Meng; Bo-Rong Pan; Xin-Han Zhao
Journal:  Int J Ophthalmol       Date:  2011-10-18       Impact factor: 1.779

3.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized.

Authors:  Christopher C Valley; Andrew K Lewis; Deepti J Mudaliar; Jason D Perlmutter; Anthony R Braun; Christine B Karim; David D Thomas; Jonathan R Brody; Jonathan N Sachs
Journal:  J Biol Chem       Date:  2012-04-10       Impact factor: 5.157

4.  Signaling through C/EBP homologous protein and death receptor 5 and calpain activation differentially regulate THP-1 cell maturation-dependent apoptosis induced by Shiga toxin type 1.

Authors:  Moo-Seung Lee; Rama P Cherla; Erin K Lentz; Dinorah Leyva-Illades; Vernon L Tesh
Journal:  Infect Immun       Date:  2010-06-01       Impact factor: 3.441

5.  Inhibition of the HIF-1 Survival Pathway as a Strategy to Augment Photodynamic Therapy Efficacy.

Authors:  Mark J de Keijzer; Daniel J de Klerk; Lianne R de Haan; Robert T van Kooten; Leonardo P Franchi; Lionel M Dias; Tony G Kleijn; Diederick J van Doorn; Michal Heger
Journal:  Methods Mol Biol       Date:  2022

6.  EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.

Authors:  Henrick Horita; Jacqueline Thorburn; Arthur E Frankel; Andrew Thorburn
Journal:  J Neurooncol       Date:  2009-05-17       Impact factor: 4.130

Review 7.  TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.

Authors:  Andrew Thorburn; Kian Behbakht; Heide Ford
Journal:  Drug Resist Updat       Date:  2008-04-18       Impact factor: 18.500

8.  High cell surface death receptor expression determines type I versus type II signaling.

Authors:  Xue Wei Meng; Kevin L Peterson; Haiming Dai; Paula Schneider; Sun-Hee Lee; Jin-San Zhang; Alexander Koenig; Steve Bronk; Daniel D Billadeau; Gregory J Gores; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2011-08-24       Impact factor: 5.157

Review 9.  Heat shock proteins-driven stress granule dynamics: yet another avenue for cell survival.

Authors:  Akanksha Verma; S Sumi; Mahendra Seervi
Journal:  Apoptosis       Date:  2021-05-12       Impact factor: 4.677

10.  The role of apoptotic cell death in the radiosensitising effect of gemcitabine.

Authors:  B Pauwels; J B Vermorken; A Wouters; J Ides; S Van Laere; H A J Lambrechts; G G O Pattyn; K Vermeulen; P Meijnders; F Lardon
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.